Skip to content
TrialScanner

NCT04678921

Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors

Phase 1CompletedNBPLead

Registry record

Lead sponsor
I-Mab Biopharma US Limited
Conditions
Solid Tumor; Metastatic Cancer; Advanced Cancer
Primary completion
Nov 21, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04678921 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04678921: Study of TJ210001 Administere... | TrialScanner